{"id":"ct-2106","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytopenias"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL577206","moleculeType":"Small molecule","molecularWeight":"365.43"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting these enzymes, CT-2106 disrupts the PI3K/AKT signaling pathway, which is involved in the proliferation and survival of cancer cells. This leads to the induction of apoptosis and inhibition of tumor growth.","oneSentence":"CT-2106 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:44.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT00059917","phase":"PHASE1","title":"Polyglutamate Camptothecin in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-01","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT00291785","phase":"PHASE1, PHASE2","title":"Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2004-01","conditions":"Colorectal Cancer","enrollment":48},{"nctId":"NCT00291837","phase":"PHASE2","title":"CT-2106 for the Second Line Treatment of Ovarian Cancer","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2004-11","conditions":"Ovarian Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CT-2106","genericName":"CT-2106","companyName":"CTI BioPharma","companyId":"cti-biopharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT-2106 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Relapsed or refractory acute myeloid leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}